Navigation Links
Weekly Digest's Investor Essentials Special Report Identifies Unique Investing Opportunities in the H1N1 'Swine Flu' Outbreak
Date:10/14/2009

PRINCETON, N.J., Oct. 14 /PRNewswire/ -- Weekly Digest (http://www.bullmarket.com/digest), a free investment research publication, announced the publication of a special report on investment opportunities in the connection with the H1N1 "Swine Flu" Outbreak, including updated outlooks for Gilead Sciences (Nasdaq: GILD), Sinovac Biotech (Amex: SVA), Dynavax Technologies (Nasdaq: DVAX), Hemispherx BioPharma (Amex: HEB), BioCryst Pharmaceuticals (Nasdaq: BCRX) and several others.

After posting large gains throughout 2009, swine flu stocks are seeing their largest pullback yet. For investors looking to position their portfolios for flu season, there are more ways to trade the flu than ever. Investors have large-cap pharmaceutical plays to choose from, and some of the more volatile, small-cap names have proven the efficacy of their drugs, while others are too far behind in their clinical trials to capitalize on the current pandemic.

To receive a free, 23-page report offering in depth analysis of the various participants in the vaccine and antiviral market, as well as some peripheral plays focusing directly on the impact of the current H1N1 swine flu pandemic, please visit the following link:

http://www.bullmarket.com/digest/signup.php?refer=pr1_swineflu

The report covers these topics and more recent reports:

-- Which small-cap swine flu plays have a real chance of benefiting in the event of a serious H1N1 outbreak and which are riding on the hype?

-- What sets Sinovac apart from other small caps pursuing vaccines and treatments to fight swine flu? How robust is Sinovac's array of products?

-- Is BioCryst likely to see revenue from its flu treatment during this flu season? How does BioCryst's peramivir fare against established drugs Tamiflu and Relenza? What are the downside risks facing BioCryst after its strong run higher?

-- Is Dynavax a real swine flu play? What do Dynavax investors need to know about the company's swine flu efforts?

-- How important is Tamiflu to Gilead's business? What are the mechanics of Gilead's Tamiflu royalty arrangement with Roche? What are the threats to Tamiflu's dominance in the antiviral market?

About Weekly Digest:

Weekly Digest is a free publication offering first-rate stock research, analysis, and commentary that is independently published by leading investment services. Subscribers receive a weekly newsletter as well as regular Special Reports, such as the new report Investor Essentials: Picking Winners for Pandemic Profits.

NOTE: This release was published by Indie Research Advisors, LLC, a registered investment advisor with CRD #131926. Interested parties may visit adviserinfo.sec.gov for additional information. Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

CONTACT: Marcia Martin, +1-888-278-5515

SOURCE Indie Research Advisors, LLC


'/>"/>
SOURCE Indie Research Advisors, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. New Study Shows Once-Monthly Boniva(R) is as Clinically Effective as Once-Weekly Fosamax(R) at Increasing Bone Mineral Density in Postmenopausal Women With Osteoporosis
2. Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight
3. After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008
4. (RED) to Launch New Way for People to Get Music in Their Lives; Weekly Delivery of Great Music Helps to Save Lives in Africa
5. Plans for Exenatide Once Weekly NDA Submission by End of First Half of 2009 Reaffirmed Following FDA Feedback
6. Exenatide Once Weekly Provided Superior Glucose Control With Weight Loss Compared to Sitagliptin or Pioglitazone in Head-to-Head DURATION-2 Study
7. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
8. Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009
9. Exenatide Once Weekly Provided Superior Glucose Control Compared to Lantus(R) in Head-to-Head DURATION-3 Study
10. Exelixis Announces September 5 Webcast of Its 2007 IASLC Investor and Analyst Briefing
11. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ALEX , has taken Kickstarter by storm, crowdfunding over $60,000 – or 120% of its original ... to be delivered to backers starting May of this year. ... ... ... Created by NAMU, a team of biomedical engineers out of ...
(Date:2/11/2016)... ROLLING MEADOWS , Ill. and INDIANAPOLIS ... major milestone for many young people, but for those ... demanding. Not only do these students juggle class schedules, ... challenges of living with type 1 diabetes. On top ... the first time. Diabetes Scholars Foundation ...
(Date:2/11/2016)... Feb. 11, 2016  AbbVie, a global biopharmaceutical ... Scholarship, designed to provide financial support for exceptional ... pursue higher education goals. Fifteen scholars will be ... school year. The AbbVie Rheumatology Scholarship is currently ... vice president, corporate social responsibility, brand and communications, ...
Breaking Medicine Technology:
(Date:2/11/2016)... , ... February 12, 2016 , ... The Journal ... up from 0.416 in 2013. The SJR uses data taken from the Scopus database ... both the number of citations received by the journal over a three year period ...
(Date:2/11/2016)... ... February 11, 2016 , ... Hall Integrative Health and ... for their simultaneous grand openings in March. All seven practices are set to ... wondering, is reversing diabetes possible? According to this 2011 CNN article it is ...
(Date:2/11/2016)... , ... February 11, 2016 , ... ... Feb. 23 webinar, “Intel’s Direct-to-Employee Benefit Model: A Case Study for Plans and ... health care system that’s partnering with Intel on value-based health benefits program Connected ...
(Date:2/11/2016)... ... , ... PharmMD CEO Robert Yeager announced today ... contract negotiations, corporate strategy and healthcare data law. Additional responsibilities will include healthcare ... breaches for the Part D Star Rating improvement and Medication Therapy Management firm. ...
(Date:2/11/2016)... Long Island, NY (PRWEB) , ... February 11, ... ... (INS) has enhanced and updated its hallmark resource, Infusion Therapy Standards of Practice, ... global leader in vein illumination with an estimated 85% share of the market, ...
Breaking Medicine News(10 mins):